These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26227279)

  • 1. A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02).
    Hiruy H; Fuchs EJ; Marzinke MA; Bakshi RP; Breakey JC; Aung WS; Manohar M; Yue C; Caffo BS; Du Y; Abebe KZ; Spiegel HM; Rohan LC; McGowan I; Hendrix CW
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1098-108. PubMed ID: 26227279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
    Mcgowan I; Cranston RD; Duffill K; Siegel A; Engstrom JC; Nikiforov A; Jacobson C; Rehman KK; Elliott J; Khanukhova E; Abebe K; Mauck C; Spiegel HM; Dezzutti CS; Rohan LC; Marzinke MA; Hiruy H; Hendrix CW; Richardson-Harman N; Anton PA
    PLoS One; 2015; 10(5):e0125363. PubMed ID: 25942472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates.
    Leyva F; Fuchs EJ; Bakshi R; Carballo-Dieguez A; Ventuneac A; Yue C; Caffo B; Du Y; Torbenson M; Li L; Mullin G; Lee L; Rohan L; Anton PA; Hendrix CW
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1089-97. PubMed ID: 26066390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.
    Dobard CW; Taylor A; Sharma S; Anderson PL; Bushman LR; Chuong D; Pau CP; Hanson D; Wang L; Garcia-Lerma JG; McGowan I; Rohan L; Heneine W
    J Infect Dis; 2015 Dec; 212(12):1988-95. PubMed ID: 26071566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).
    Robinson JA; Marzinke MA; Fuchs EJ; Bakshi RP; Spiegel HML; Coleman JS; Rohan LC; Hendrix CW
    J Acquir Immune Defic Syndr; 2018 Feb; 77(2):175-182. PubMed ID: 29135651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).
    McGowan I; Hoesley C; Cranston RD; Andrew P; Janocko L; Dai JY; Carballo-Dieguez A; Ayudhya RK; Piper J; Hladik F; Mayer K
    PLoS One; 2013; 8(4):e60147. PubMed ID: 23573238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
    Carballo-Diéguez A; Balán IC; Brown W; Giguere R; Dolezal C; Leu CS; Marzinke MA; Hendrix CW; Piper JM; Richardson BA; Grossman C; Johnson S; Gomez K; Horn S; Kunjara Na Ayudhya RP; Patterson K; Jacobson C; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla C; Lama J; McGowan I; Cranston RD
    PLoS One; 2017; 12(7):e0181607. PubMed ID: 28750059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.
    Delany-Moretlwe S; Lombard C; Baron D; Bekker LG; Nkala B; Ahmed K; Sebe M; Brumskine W; Nchabeleng M; Palanee-Philips T; Ntshangase J; Sibiya S; Smith E; Panchia R; Myer L; Schwartz JL; Marzinke M; Morris L; Brown ER; Doncel GF; Gray G; Rees H
    Lancet Infect Dis; 2018 Nov; 18(11):1241-1250. PubMed ID: 30507409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.
    Bunge KE; Dezzutti CS; Hendrix CW; Marzinke MA; Spiegel HML; Moncla BJ; Schwartz JL; Meyn LA; Richardson-Harman N; Rohan LC; Hillier SL
    J Int AIDS Soc; 2018 Aug; 21(8):e25156. PubMed ID: 30101439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
    Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rectal microbicide development.
    McGowan I
    Curr Opin HIV AIDS; 2012 Nov; 7(6):526-33. PubMed ID: 23032732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
    Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
    AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparative Pre-Phase I Study of the Impact of Gel Vehicle Volume on Distal Colon Distribution, User Experience, and Acceptability.
    Weld ED; Hiruy H; Guthrie KM; Fava JL; Vargas SE; Buckheit K; Buckheit R; Spiegel H; Breakey J; Fuchs EJ; Hendrix CW
    AIDS Res Hum Retroviruses; 2017 May; 33(5):440-447. PubMed ID: 27824253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.
    Carballo-Diéguez A; Giguere R; Dolezal C; Leu CS; Balán IC; Brown W; Rael C; Richardson BA; Piper JM; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla CD; Lama JR; McGowan I; Cranston RD;
    AIDS Behav; 2017 Dec; 21(12):3336-3345. PubMed ID: 29119473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women.
    McGowan I; Cranston RD; Mayer KH; Febo I; Duffill K; Siegel A; Engstrom JC; Nikiforov A; Park SY; Brand RM; Jacobson C; Giguere R; Dolezal C; Frasca T; Leu CS; Schwartz JL; Carballo-Diéguez A
    PLoS One; 2016; 11(6):e0158310. PubMed ID: 27362788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.
    Herold BC; Chen BA; Salata RA; Marzinke MA; Kelly CW; Dezzutti CS; McGowan I; Galaska B; Levy L; Piper JM; Hillier S; Hendrix CW
    Clin Infect Dis; 2016 Feb; 62(3):375-382. PubMed ID: 26508513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).
    Robinson JA; Marzinke MA; Bakshi RP; Fuchs EJ; Radebaugh CL; Aung W; Spiegel HM; Coleman JS; Rohan LC; Hendrix CW
    AIDS Res Hum Retroviruses; 2017 Apr; 33(4):339-346. PubMed ID: 27809557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and delivery of anti-HIV rectal microbicides: advances and challenges.
    Nunes R; Sarmento B; das Neves J
    J Control Release; 2014 Nov; 194():278-94. PubMed ID: 25229988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression.
    Romas L; Birse K; Mayer KH; Abou M; Westmacott G; Giguere R; Febo I; Cranston RD; Carballo-Diéguez A; McGowan I; Burgener A
    AIDS Res Hum Retroviruses; 2016; 32(10-11):1005-1015. PubMed ID: 27316778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterosexual anal intercourse has the potential to cause a significant loss of power in vaginal microbicide effectiveness studies.
    McGowan I; Taylor DJ
    Sex Transm Dis; 2010 Jun; 37(6):361-4. PubMed ID: 20514687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.